Botensilimab + Balstilimab for Rectal Cancer

(RECTIFY-1 Trial)

This trial tests a combination of two treatments, botensilimab and balstilimab, for individuals with early-stage rectal cancer that hasn't spread to lymph nodes. The goal is to determine if these treatments can shrink tumors before surgery. It targets those with microsatellite stable (MSS) cancer, where cells properly repair DNA errors. Individuals with early rectal cancer confirmed by MRI and who are surgical candidates might be suitable participants. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group.

A previous study found that the combination of botensilimab and balstilimab was well tolerated. Importantly, participants experienced no severe grade 4 events or unresolved immune-related problems. Furthermore, researchers observed no new side effects and no treatment-related deaths. This treatment differs from other similar drugs, potentially resulting in fewer side effects. Overall, the safety profile is considered manageable, indicating it should be safe for most patients.¹²³⁴⁵

Unlike the standard treatments for rectal cancer, which typically involve chemotherapy and radiation, Botensilimab and Balstilimab are unique because they harness the body's immune system to fight cancer. Botensilimab is an innovative agent that enhances immune response by targeting specific immune checkpoints, while Balstilimab blocks the PD-1 pathway, helping the immune system detect and attack cancer cells more effectively. Researchers are excited about these treatments because they offer a new way to potentially improve outcomes for patients by using the body's natural defenses, which could lead to more targeted and less toxic cancer therapy options.

Research has shown that the combination of botensilimab and balstilimab holds promise for patients with microsatellite-stable (MSS) colorectal cancer. In earlier studies, approximately 71% of these patients experienced significant tumor shrinkage. Additionally, this treatment combination resulted in a 42% survival rate over two years and an average survival time of nearly 21 months. It has proven effective for both early and advanced stages of the disease. This trial will specifically evaluate the effectiveness of botensilimab and balstilimab in treating early rectal cancer.¹²³⁵⁶